EASO Collaborating Centres for Obesity Management (COMs)
Application Form
The Concept
Obesity is recognised as a global epidemic and the most prevalent metabolic disease world-wide. However,
specialised obesity services are not widely available in Europe and obesity care can therefore vary enormously
across European regions. In response to this situation, EASO has developed a network of accredited specialised
obesity centres, where the quality and efficacy of the care offered to patients are of the highest standards.
Under the EASO Collaborating Centres for Obesity Management (COM) scheme, centres will be accredited in
accordance with accepted European and academic guidelines. Our aim is to provide physicians, health-care
policy makers and health-care providers with authoritative criteria for the development of Obesity Management
Centres across Europe, recognized by national health authorities. Accreditation will be granted for a three year
period, after which time re-assessment will be undertaken.
For further information, please refer to the EASO COM Criteria Paper (Obes Facts 2011;4:329–333) or visit
www.easo.org
Who Should Apply?
The EASO COM network will include university, public and private clinics. Each centre must comply with clearly
defined requirements and work in close collaboration for the better management of all obese patients. Each
accredited centre must ensure that the obese and overweight patient is managed by a holistic team of
specialists and will receive comprehensive state-of-the-art clinical care. Furthermore, the participating centres,
under the umbrella of EASO, will work closely for quality control, data collection and analysis, as well as
education and research for the advancement of obesity care and obesity science.
Each centre will be expected to:













Implement state-of-the art evidence-based care
for obese patients
Monitor all obesity- related medical conditions and
risk factors
Provide high quality patient and public information
Improve access to care pathways by optimizing
referral processes and developing close working between levels of care
Develop comprehensive multidisciplinary local
collaboration
Facilitate, and empower patients to make healthy
lifestyle changes: develop therapeutic education
Educate staff about treating patients with obesity
Encourage development of and support Patient
Associations, by sharing experience and expertise
Offer or collaborate with preventive care services
Promote obesity related knowledge and awareness
among the public and health care providers
Improve the collaboration interface between
clinical researchers and scientists
Integrate health care, teaching and research
Facilitate clinical research projects
Why Should You Apply?
Each member centre will be accredited, for a three year period, as having met comprehensive criteria as set out
by EASO and according to recognised European management guidelines – and will therefore be recognised as a
leading obesity management centre in Europe. Accredited centres will have the opportunity to:
 contribute to the development of EASO pan-European protocols for the evaluation of obese patients
 contribute to the development of consensus statements/guidelines on specialised aspects of obesity







management
contribute to obesity education across Europe
participate in an EASO led pan-European scientific/clinical exchange programme
participate in EASO facilitated Clinical Trials and Pilot Studies
participate in EASO coordinated research projects
participate in COM ‘Summit Meetings’ at each ECO (European Congress on Obesity)
access and contribute to an EASO pan-European system of data collection and analysis
access a web-based COM community where each centre can post job vacancies and highlight the key
capabilities and features of the centre
EUROPEAN ASSOCIATION FOR THE STUDY OF OBESITY
REGISTERED CHARITY NUMBER 1111288
How Can You Apply?
All interested centres are required to complete the comprehensive application form below, which will be
assessed by the EASO OMTF (Obesity Management Task Force) – applications will be assessed twice per year.
Thereafter, feedback will be given and where necessary assessment site visits will be conducted. No application
fee will be charged. However, for those centres that require an assessment site visit, the applicant centre will
be expected to cover the travel and accommodation costs of a maximum of two EASO OMTF members.
EASO COM Application Form
Oslo University Hospital
Name of Institution:
Address:
Department of Endocrinology, Obesity, and Preventive Medicine
P O Box 4956 Nydalen
Town/City:
0424 Oslo
Country:
Norway
Website:
www.oslo-universitetssykehus.no
Lead Contact:
Mette Svendsen
Registered dietitian
Position of Lead
Contact:
Yes
Member of EASO
National Association:
Telephone:
+4723016653
Fax:
+4722119975
mesven@ous-hf.no
Email:
Signature of Lead
Contact:
16.12.2011
Date of Submission:
EUROPEAN ASSOCIATION FOR THE STUDY OF OBESITY
REGISTERED CHARITY NUMBER 1111288
EASO COM Requirements
General Requirements
Number of obese patients seen per annum
Number of new obese patients per annum
Patients: Outline
patient profile and
selection procedure.
Facility Location:
Outline facilities and
geographical
distribution of sites.
Number of massively obese patients (BMI > 40) per annum
5500
consultations
1600
Number of obese children/adolescents seen per annum
8-900
cases
0
Specific cases: rare diseases
Yes
Is the facility a Centre or Clinic?
Centre
-within a university hospital
Yes
-within a general hospital
No
-within a larger department (internal medicine, endocrinology...)
Yes
If yes, give details.
The Department of Endocrinology, Obesity and Preventive Medicine
was established in September 2011 as part of the Oslo University
Hospital change process in which several hospitals including Aker,
Ullevaal, Rikshospitalet and Radiumhospitalet were united to one
hospital. Among nine sections in the Department, the Section of
Morbid Obesity and Bariatric Surgery and the Section of Preventive
Cardiology offer management of obesity. Presently the Morbid
Obesity and Bariatric Surgery and Preventive Cardiology sections are
located at two sites. As part of the further development of the
united Department, plans are made for a one-site facility.
Number of beds dedicated to obesity
8
Number of weekly clinics dedicated to obesity
2
new
Outline contacts with pediatric team
Children and adolescents are evaluated at the Department of Pediatrics, Oslo
University Hospital, until the age of 18 years, and thereafter referred to Preventive
Cardiology for further follow-up.
Number of MDs in the dept involved in obesity management
8
Staff Specifications:
Give overview of all
staff involved in the
delivery of the Obesity
Management service.
Are all staff members of
the relevant EASO
National Association?
Links to GPs: Outline
Patient Pathway
System.
Number with IASO SCOPE certification
1
Number of Dieticians
4
Number of Psychologists
1
Number of Physical educators
3
First/second/third referral
The Department is the first referral center for general practitioners in Oslo and
around Oslo, serving a population of about 2 million. The Section of Morbid Obesity
and Bariatric Surgery has been assigned tertiary care responsibilities by the Norwegian
South-East Regional Health Authority to treat severely obese patients. After
assessments and/or treatment the patients are referred back to their general
practitioners. Treatment summaries are sent to referring general practitioners .
EUROPEAN ASSOCIATION FOR THE STUDY OF OBESITY
REGISTERED CHARITY NUMBER 1111288
Links to other Medical
Services and Facilities:
Outline all relevant
systems and structured
links.
The Department is linked to all relevant services and facilities at the
Oslo University Hospital.
EASO COM Requirements: Equipment and Tools Appropriate for Obese Patients
Tool (Essential)
Appropriate cuffs for blood pressure
measurement (>34cm)

Scales with adequate weight capacity (> 200 kg)

Armless chairs, high firm sofas in waiting rooms

Wide examination tables

Beds for very obese patients >200kg

Stretchers adapted to very obese persons

Sleep apnoea monitors on site or at affiliated
facilities

Food frequency questionnaire and/or dietary
intake recording and assessment

Questionnaires concerning depression, eating
attitudes and disorders, physical activity, quality
of life (QOL)

Access to accredited hormonal and molecular
genetics laboratories

Access to additional relevant diagnostic
procedures adapted to the very obese persons,
such as:
X-ray
Ultrasound
CT and NMR Scanning
Endoscopy
Cardiac and Pulmonary Assessment
Nuclear Medicine
()
Comment
()
Comment
()
Comment






Tool (Recommended)
Pedometers

Skinfold calipers

Body composition analysis [Bio-impedance, dualenergy X-ray absorptiometry (DEXA)]

EUROPEAN ASSOCIATION FOR THE STUDY OF OBESITY
REGISTERED CHARITY NUMBER 1111288
Indirect calorimetry
Tool (Optimal)

()
Comment
Hydrodensitometry
Air displacement plethysmography
EASO COM Requirements
Additional Requirements
Treatment Modalities: Outline
your Institution’s spectrum of
clinically proven treatment
options (to include the treatment
of complications).
The obesity treatment is based on good clinical care according to the
policy of the Oslo University Hospital and evidence-based guidelines
recommended by the Norwegian Health Department and EASO/OMTF
guidelines.
The Department has a multi-disciplinary team that includes physicians
specialized in obesity, lipidology, endocrinology, cardiology, public health
and bariatric surgeons. The Department has assessment and treatment
options related to hypertension (24-hours blood pressure measurement),
cardiac function (bicycle exercise test, cardiac ultrasound), risk factors for
cardiovascular disease (quit smoking therapy, dietary and pharmacological
treatment of blood lipids) and management of diabetes.
Educational Tools: Outline the
educational opportunities and
options offered by your
Institution.
The educational opportunities given in the management of the obese
patients include individual and group based multidisciplinary therapy
lasting for at least one year, printed materials and e-mail links as well as
preoperative courses to prepare for surgery and postoperative follow up
courses lasting for five years.
In addition the patients are offered pharmacotherapy when indicated, and
referral to local or specialized opportunities for organized physical
activity.
Affiliation with an accredited
Bariatric Surgery Centre: Outline
the scope and nature of any such
affiliations.
The Section of Morbid Obesity and Bariatric Surgery is accredited for
bariatric surgery and has performed more than 1400 bariatric operations
mostly laparascopic gastric bypass, since 2004. The section can perform all
kinds of bariatric surgical precedures laparoscopically and is the only
center in Norway performing laparoscopic duodenal switch. Bariatric
surgery is performed according to the EASO/FSO criteria.
Data Collection and Management:
Outline your Institution’s data
collection and management
systems.
All patients operated at Morbid Obesity and Bariatric surgery are
registrated in a prospective database.
In cooperation with the Department of Genetics at the Oslo University
Hospital, Preventive Cardiology established a database and biobank
including 1000 obese adults as part of a research program.
We plan to develop a unified prospective register for management and
outcome effects of obesity treatment at the national level together with
other obesity management centres in Norway.
Education and Training and
Research: Outline your
Institution’s post-graduate
training programmes and
Education and training
The Section of Morbid Obesity and Bariatric Surgery conducts courses for
doctors and nurses from Norway and the rest of the world. About 4-6
courses are held each year with about 15 attendees in each course, mostly
EUROPEAN ASSOCIATION FOR THE STUDY OF OBESITY
REGISTERED CHARITY NUMBER 1111288
research capabilities/projects.
from Europe or the Middle East.
Preventive Cardiology conducts an annual course in Preventive Cardiology
offered to postgraduate physicians. Registered dietitians at the
Department are responsible for education of dietitians in obesity
management at the University of Oslo. A course in obesity evaluation and
treatment is offered every other year.
Research
The Section of Morbid Obesity and Bariatric surgery participates in many
clinical studies and is associated with research groups at the University of
Oslo and Bergen, the Sahlgrenska University Hospital in Gothenburg,
Sweden, and Imperial College in London to name a few. Since 2004 more
than 30 publications have originated from the Department of Morbid
Obesity and Bariatric surgery. In 2010 the first doctoral thesis by Dr.
Erlend Aasheim was based on work done at the Department of Morbid
Obesity and Bariatric surgery. At this time there are three individuals
working on their doctoral thesis at the Department.
The Preventive Cardiology section participates in many clinical studies as
reflected in the publication list, and is associated with research groups at
the Institute of Nutrition at the University of Oslo, Sahlgrenska University
Hospital in Gothenburg, Sweden and others. Preventive Cardiology has
participated in multi-centre studies addressing the efficacy of
pharmacological treatment of obesity, hyperlipidemia, hypertension,
smoking cessation as well as investigator initialized studies among patients
with high metabolic risk. In 2009, Mette Svendsen a registered dietitian at
Preventive Cardiology successfully defended her doctoral degree based on
work done in obesity treatment conducted at the Preventive Cardiology
section. At this time one physician is working with her doctoral thesis.
Selected references from Preventive Cardiology last 5 years:
1.
2.
3.
4.
5.
6.
7.
8.
9.
Tonstad S. Rimonabant: a cannabinoid receptor blocker for the
treatment of metabolic and cardiovascular risk factors. Nutr
Metab Cardiovasc Dis 2006; 16: 156-62.
Svendsen M, Tonstad S. Accuracy of food intake reporting in obese
subjects with metabolic risk factors. Brit J Nutr 2006; 95: 640-9.
Tonstad S, Anderssen S, Khoury J, Ose L, Reseland J, Retterstøl L.
Weight concerns and beliefs about obesity in the Norwegian
population. Scand J Food & Nutrition 2006; 50: 25-9.
Tonstad S. Is rimonabant a safe and effective therapy for sustained
weight loss and improved cardiometabolic risk factors? Nat Clin
Pract Cardiovasc Med 2006; 3: 364-5 (erratum Nat Clin Pract
Cardiovasc Med 2006; 3: 520).
Rissanen A. Effect of orlistat on weight regain and cardiovascular
risk factors following a very-low-energy diet in abdominally obese
patients. A 3-year-randomized placebo- controlled study. Diabetes
Care 2007; 30: 27-32.
Håheim LL, Tonstad S, Hjermann I, Leren P, Holme I.
Predictiveness of body mass index for fatal coronary heart disease
in men according to length of follow-up: A 21-year prospective
cohort study. Scand J Public Health 2007; 35: 4-10.
Tonstad S, Sandvik E, Larsen PGL, Thelle D. Gender differences in
the prevalence and determinants of the metabolic syndrome in
screened subjects at risk for coronary heart disease. Metab Syndr
Relat Disord 2007; 5: 174-82.
Holme I, Haaheim LL, Sogaard AJ, Lund Larsen PG, Tonstad S.
Repeated weight loss is associated with the metabolic syndrome
and diabetes: Results of a 28 year re-screening of men in the Oslo
Study. Metab Syndr Relat Disord 2007; 5: 127-35.
Holme I, Tonstad S, Søgård AJ, Larsen PGL, Håheim LL. Leisure
time physical activity in middle age predicts the metabolic
EUROPEAN ASSOCIATION FOR THE STUDY OF OBESITY
REGISTERED CHARITY NUMBER 1111288
10.
11.
12.
13.
14.
15.
16.
17.
18.
19.
20.
21.
22.
23.
24.
syndrome in old age: results of a 28-year follow-up of men in the
Oslo Study. BMC Public Health 2007; 7:154.
Tonstad S, Retterstøl K, Ose L, Öhman P, Lindberg M, Svensson M.
The dual peroxisome proliferator-activated receptor / agonist
tesaglitazar further improves the lipid profile in dyslipidaemic
subjects treated with atorvastatin. Metabolism 2007; 56: 1285-92.
Erondu N, Addy C, Lu K, Mallick M, Musser B, Gantz I, Proietto J,
Astrup A, Toubro S, Rissannen AM, Tonstad S, Haynes WG,
Gottesdiener KM, Kaufman KD, Amatruda JM, Heymsfield SB.
NPY5R antagonism does not augment the weight loss efficacy of
orlistat or sibutramine. Obesity 2007; 15: 2027-42.
Svendsen M, Blomhoff R, Holme I, Tonstad S. The effect of an
increased intake of vegetables and fruit on weight loss, blood
pressure and antioxidant defense in subjects with sleep related
breathing disorders. Eur J Clin Nutr 2007; 61: 1301-11.
Fagerberg B, Schuster H, Birketvedt GS, Tonstad S, Öhman P,
Gause-Nilsson I on behalf of the SIR Study Group. Improvement of
postprandial lipid handling and glucose tolerance in a non-diabetic
population by the dual PPAR/ agonist tesaglitazar. Diab Vasc Dis
Res 2007; 4: 174-80.
Tonstad S. Identifying obese women most at risk from
cardiovascular disease. Int J Obes 2007; 31 (Suppl 2): S19-S25.
Svendsen M, Rissanen A, Richelsen B, Rössner S, Hansson F,
Tonstad S. Effect of orlistat on eating behavior among participants
in a 3-year weight maintenance trial. Obesity 2008; 16: 327-33.
Madsen EL, Rissanen A, Bruun JM, Skogstrand K, Tonstad S,
Hougaard DM, Richelsen B. Weight loss larger than 10% is needed
for general improvement of levels of circulating adiponectin and
markers of inflammation in obese subjects. A 3-year weight loss
study. Eur J Endocrin 2008; 158: 179-87.
Søgaard AJ, Meyer HE, Tonstad S, Håheim LL, Holme I. Weight
cycling and risk of forearm fractures. a 28-year follow-up of men in
the Oslo Study. Am J Epidemiol 2008; 167: 1005-13.
Ellingsen I, Hjerkinn E. M., Seljeflot I, Arnesen H, Tonstad S.
Consumption of fruit and berries is inversely associated with
carotid atherosclerosis in elderly men. Brit J Nutr 2008; 99:674-81.
Erratum in: Br J Nutr. 2008; 99 :697
Schuster H, Fagerberg B, Edwards S, Halmos T, Lopatynski J,
Stender S, Birketvedt GS, Tonstad S, Gause-Nilsson I, Halldórsdóttir
S, Öhman KP for the SIR Investigators. Tesaglitazar, a dual
peroxisome proliferator-activated receptor / agonist, improves
apolipoprotein levels in non-diabetic subjects with insulin
resistance. Atherosclerosis 2008; 197: 355-62.
Jenssen TG, Tonstad S, Claudi T, Midthjell K, Cooper J. The gap
between guidelines and practice in the treatment of type 2
diabetes. A nationwide survey in Norway. Diab Res Clin Prac 2008;
80: 314-20
Hustvedt BE, Svendsen M, Løvø A, Ellegaard L, Hallén J, Tonstad S.
Validation of ActiReg to measure physical activity and energy
expenditure against doubly labelled water in obese persons. Brit J
Nutr 2008; 100: 219-26.
Dørum A, Tonstad S, Liavaag A, Michelsen TM, Hildrum B, Dahl AA.
Bilateral oophorectomy before 50 years of age is significantly
associated with the metabolic syndrome and Framingham risk
score: a controlled, population-based study. Gynecol Oncol 2008;
109: 377-83.
Pollestad Kolsgaard M, Andersen LF, Tonstad S, Brunborg C,
Wangensteen T, Joner G. Ethnic differences in metabolic syndrome
among overweight and obese children and adolescents: the Oslo
Adiposity Intervention Study. Acta Pediatr 2008; 97: 1557-63.
Aasen G, Fagertun H, Tonstad S, Halse J. Leg fat mass as
measured by dual X-ray absorptiometry (DXA) impacts insulin
resistance differently in obese women versus men. Scand J Clin
Invest 2009; 69: 181-9
EUROPEAN ASSOCIATION FOR THE STUDY OF OBESITY
REGISTERED CHARITY NUMBER 1111288
25. Michelsen TM, Pripp AH, Tonstad S, Trope CG, Dorum A. Metabolic
syndrome after risk-reducing salpingo-oophorectomy in women
with high risk of hereditary breast ovarian cancer. A controlled
observational study. Eur J Cancer 2009; 45: 82-9.
26. Svendsen M, Helgeland M, Tonstad S. The long-term influence of
orlistat on dietary intake in obese subjects with components of
metabolic syndrome. J Hum Nutr Diet 2009; 22: 55-63.
27. Malterud K, Tonstad S. Preventing obesity; challenges and pitfalls
for health promotion. Patient Educ Couns 2009; 76: 254-9
28. Wangensteen T, Kolsgaard ML, Mattingsdal M, Joner G, Tonstad S,
Undlien D, Retterstol L. Mutations in the melanocortin 4 receptor
(MC4R) gene in obese patients in Norway. Exp Clin Endocrinol
Diabetes 2009; 117: 266-73
29. Tonstad S, Butler T, Yan R, Fraser GE. Type of vegetarian diet,
body weight and prevalence of type 2 diabetes. Diabetes Care
2009; 32: 791-6.
30. Tonstad S. Cigarette smoking, smoking cessation and diabetes.
Diabetes Res Clin Pract 2009; 85: 4-13.
31. Liavaag AH, Tonstad S, Pripp AH, Tropé C, Dørum A. Prevalence
and determinants of metabolic syndrome and elevated Framingham
risk score in epithelial ovarian cancer survivors: a controlled
observational study. Int J Gynecol Cancer 2009; 19: 634-40.
32. Kolsgaard MLP, Wangensteen T, Joner G, Brunborg C, Holven K,
Aukurst P, Halvorsen B, Tonstad S. Elevated visfatin levels in
overweight and obese children and adolescents with metabolic
syndrome. Scand J Clin Invest 2009; 69: 858-64.
33. Halvorsen B, Heggen E, Ueland T, Smith C, Sandberg WJ, Damås
JK, Otterdal K, Tonstad S, Aukrust K. Treatment with the PPARgamma agonist rosiglitazone down-regulates interleukin-1 receptor
antagonist in individuals with metabolic syndrome. Eur J Endocrinol
2010; 162: 267-73.
34. Hampson SE, Tonstad S, Irgens L, Meltzer HM, Vollrath M. Mothers’
negative affectivity during pregnancy and obesogenic food choices
for their infants. Int J Obes 2010; 34: 327-31.
35. Aronne LJ, Tonstad S, Moreno M, Gantz I, Erondu N, Suryawanshi S,
Molony C, Sieberts SK, Nayee J, Meehan AG, Shapiro D, Heymsfield
S, Kaufman KD, Amatruda J. A clinical trial assessing the safety and
efficacy of the CB1R inverse agonist taranabant in obese and
overweight patients: high-dose study. Int J Obes 2010; 34: 919-35
36. Klemsdal TO, Nerland H, Holme I, Pedersen TR, Tonstad S. Effects
of a low-glycemic load diet versus a low-fat diet in subjects with
and without the metabolic syndrome. Nutr Metab Cardiovasc Dis
2010; 20: 195-201.
37. Peterson RM, Beeson L, Shulz E, Firek A, De Leon M, Balcazar H,
Tonstad S, Cordero-MacIntyre ZR. Impacting obesity and glycemic
control using a culturally sensitive diabetes education program in
Hispanic patients with type 2 diabetes. International Journal Body
Composition Research 2010; 8: 85-94.
38. Vollrath M, Tonstad S, Rothbart MK, Hampson S. Infant
temperament is associated with potentially obesogenic diet at 18
months. Int J Pediatr Obes 2010; Epub ahead of print
39. Solaas K, Legry V, Retterstol L, Berg PR, Holven KB, Ferrières J,
Amouyel P, Lien S, Romeo J, Valtueña J, Widhalm K, Ruiz JR,
Dallongeville J, Tonstad S, Leren, TP Rootwelt H, Halvorsen BL,
Nenseter MS, Birkeland KI, Thorsby PM, Meirhaeghe A, Nebb HI.
Suggestive evidence of associations between liver X receptor β
polymorphisms with type 2 diabetes mellitus and obesity in three
cohort studies: HUNT2 (Norway), MONICA (France) and HELENA
(Europe). BMC Medical Genetics 2010, 11:144
40. Svendsen M, Tonstad S. Orlistat after initial dietary/behavioral
treatment: changes in body weight and dietary maintenance in
subjects with sleep related breathing disorders. Nutr J. 2011 Mar
8;10:21
41. Kolsgaard ML, Joner G, Brunborg C, Anderssen SA, Tonstad S,
EUROPEAN ASSOCIATION FOR THE STUDY OF OBESITY
REGISTERED CHARITY NUMBER 1111288
42.
43.
44.
45.
46.
47.
Andersen LF. Reduction in BMI z-score and improvement in
cardiometabolic risk factors in obese children and adolescents. The
Oslo Adiposity Intervention Study- a hospital/public health nurse
combined treatment. BMC Pediatr 2011; 11: 47
Singh P, Haddad E, Tonstad S, Fraser G. Does excess body fat
maintained after the seventh decade decrease life expectancy? J
Am Geriatr Soc 2011; 59: 1003-11
Norheim OF, Gjelsvik B, Klemsdal TO, Madsen S, Meland E,
Narvesen S, Negård A, Njølstad I, Tonstad S, Ulvin F, Wisløff T.
Norway’s new principles for primary prevention of cardiovascular
disease: age differentiated risk thresholds. BMJ 2011; 342:d3626
doi
Tonstad S, Després J-P. Treatment of lipid disorders in obesity.
Expert Rev Cardiovasc Ther 2011; 9: 1069-80
Tonstad S, Stewart K, Oda K, Batech M, Herring RP, Fraser GE.
Vegetarian diets and incidence of type 2 diabetes. Nutr Metab
Cardiovasc Dis 2011 Oct 7 [Epub ahead of print]
Karlsen TI, Tveitå EK, Røisli J, Natvig GK, Tonstad S, Hjelmesæth
J. The validity of the SF-36 in patients with morbid obesity.
Obesity Facts, Accepted
Svendsen M, Hustvedt BE, Tonstad S. Physical activity in treatment
seeking obese subjects with a high metabolic risk profile. Accepted
International Journal Body Composition Research
Selected references from Morbid Obesity and Bariatric Surgery last 5 years
Søvik TT, Aasheim ET, Taha O, Engstrøm M, Bjørkman S,
Kristinsson J, Birkeland K, Mala T, Olbers T. Weight loss,
cardiovascular risk factors, and quality of life after gastric bypass
and duodenal switch – a randomized trial. Ann Intern Med 2011;
155: 281-191.
2. Pournaras D, Aasheim E, Søvik T, Andrews R, Mahon D, Welbourn
R, Olbers T, le Roux CW. Lowering of remission rates of type 2
diabetes after bariatric surgery: impact of the 2009 ADA consensus
definitions. Br J Surg 2011; epub ahead of print
3. Ågesen TH, Berg M, Thiis-Evensen E, Nesbakken A, Cekaite L, Lind
GE, Nesland JM, Bakka A, Mala T, Hauss HJ, Fetveit T, Lothe RA,
Skotheim RI. Transcriptional profiling of early and late onset
colorectal cancer identifies potential cancer susceptibility genes.
Genes and Immun 2011; epub ahead of print.
4. Hølmebakk T, Solbakken A, Mala T, Nesbakken A. Accuracy of
prognostication in patients with incurable abdominal malignancy as
assessed by surgeons. Eur J Surg Oncol 2011; 37: 571-5.
5. Hofsø D, Aasheim ET, Søvik T, Jakobsen GS, Johnson LK, Aas AT,
Sandbu R, Kristinsson J og Hjelmesæth J. Laparososopisk
biliopankreatisk avledning med duodenal omkopling. Tidsskr Nor
legeforen 2011: 131: 1887-1892.
6. Schou CF, Søvik T, Aasheim E, Kristinsson J, Mala T. Tidsskr Nor
legefore 2011; 131: 1882-1886.
7. Hewitt S, Weidanz F, Westgeest H, Ruza I, Ciferska H, Pasquet F,
Salomäki S, Olsen E. Effect of bariatric surgery on sulfur amino
acids and glutamate. Eur J Intern Med 2011; 22: 238-40.
8. Aasheim ET, Elshorbagy A, Diep LM, Søvik T, Mala T, ValdiviaGarcia M, Olbers T, Bøhmer T, Birkeland KI, Refsum H. European
School of Internal Medicine (ESIM) in Brighton Experiences and
reflections. Br J Nutr 2011; May 4: 1-10.
9. Aasheim ET, Søvik TT. Global trends in body-mass index. Lancet
2011; 377: 1916-17.
10. Mala T. Invited Editorial Comment: Self-expanding metallic stents
as bridge to surgery in obstructing colorectal cancer. Br J Surg.
2011. 98(2):281
11. Nesbakken A, Kristinsson J, Svindland A, Lunde OC. Endoscopic
snare resection followed by laser ablation in the treatment of
large, sessile rectal adenomas. Scand J Surg. 2011;100(2):99-104.
1.
EUROPEAN ASSOCIATION FOR THE STUDY OF OBESITY
REGISTERED CHARITY NUMBER 1111288
12. Olstad R, Florholmen J, Svartberg J, Rosenvinge JH, Birketvedt GS.
Leptin in the General Population, Differences in Sex Hormones,
Blood Lipids, Gender and Life Style Characteristics. The Open
Behavioral Science Journal 2011; 5: 8-15.
13. Vangen Skyrud R, Aaseth J, Birketvedt GS. Outpatient
multidisiplinary treatment of morbidly obese patients; a two year
retrospective study. Open Behavioral Science Journal 2011: Vol 5,
page 28-32.
14. Søvik TT, Taha O, Aasheim ET, Engström M, Kristinsson J, Björkman
S, Schou CF, Lönroth H, Mala T, Olbers T. Randomized clinical trial
of laparoscopic gastric bypass versus duodenal switch for
superobesity. Br J Surg 2010; 97: 160-6.
15. Aasheim ET, Frigstad SO, Søvik TT, Birkeland KI, Haukeland JW.
Hyperinsulinemic hypoglycemia and liver cirrhosis presenting after
duodenal switch: a case report. Surg Obes Relat Dis 2010; 6: 441-3
16. Søvik TT, Irandoust B, Birkeland KI, Aasheim E, Schou CF,
Kristinsson J, Mala T.Type 2 diabetes and metabolic syndrome
before and after gastric bypass.Tidsskr Nor Legeforen 2010; 130:
1347-50.
17. Mårin P, Birketvedt GS. Cortisol regulation in the metabolic
syndrome. A novel therapeutic approach. Imunn, Endoc & Metab.
Agents in Med. Chem. 2010, 10
18. Berg M, Danielsen, SA Ahlquist T, Merok M, Ågesen TH, Vatn MH,
Mala T, Sjo OH, Bakka A, Moberg I, Fetveit T, Mathisen Ø, Husby A,
Sandvik O, Nesbakken A, Thiis-Evensen E, Lothe RA. DNA sequence
profiles of the colorectal cancer critical gene set: KRAS-BRAFPIK3CA-PTEN-TP53 related to age at disease onset. Plos one 2010;
5: e13978
19. Søvik TT, Aasheim ET, Olbers T. Randomized clinical trial of
laparoscopic gastric bypass versus laparoscopic duodenal switch for
superobesity Br J Surg 2010; 97: (Response to Letter to the Editor)
20. Aasheim ET. The alcohol factor in Wernicke’s encephalopathy post
bariatric surgery. Ann Surg 2010; 251: 993–4.
21. Aasheim ET, Hofsø D, Søvik TT. Vitamin supplements after bariatric
surgery. Clin Endocrinol 2010; 72: 134-5.
22. Aasheim ET, Björkman S, Søvik TT, Engström M, Hanvold S, Mala T,
Olbers T, Bøhmer T. Vitamin status after bariatric surgery: a
randomized study of gastric bypass and duodenal switch. Am J Clin
Nutr 2009; 90: 15–22.
23. Søvik TT, Aasheim ET, Kristinsson J, Schou CF, Diep LM, Nesbakken
A, Mala T. Establishing laparoscopic Roux-en-Y gastric bypass:
perioperative outcome and characteristics of the learning curve.
Obes Surg 2009; 19: 158–65.
24. Hjelmesæth J, Hofsø D, Aasheim ET, Jenssen T, Moan J Hager H,
Røislien J, Bollerslev J. Parathyroid hormone, but not vitamin D, is
associated with the metabolic syndrome in morbidly obese
subjects. Cardiovasc Diabetol 2009; 8: 7.
25. Skogøy K, Laurini R, Aasheim ET. Pregnancy shortly after bariatric
surgery. Tidsskr Nor Laegeforen 2009; 129: 534–6.
26. Aasheim ET, Hove AB, Bøhmer T. Thiamine assay values: influence
of anticoagulants and hemoglobin. Scand J Clin Lab Invest 2009;
69: 460–1.
27. Aasheim ET. Peculiarities of Wernicke encephalopathy after
bariatric surgery. Ann Surg 2009; 249: 1066–7.
28. Aasheim T. Wernicke Encephalopathy after bariatric surgery: a
systematic review. Ann Surg 2008; 248: 714-720
29. Aasheim E, Søvikk TT, Bakke EF. Night blindness after duodenal
switch. Surg Obes Relat Dis 2008; 4: 685-6
30. Aasheim E, Hofsø D, Hjelmesæth J, Birkeland KI, Bøhmer T.
Vitamin status in morbidly obese patients: a cross sectional study.
Am J Clin Nutr 2008; 87: 362-9.
31. Aasheim E, Hofsø D, Hjelmesæth J, Sandbu R. Peripheral
neuropathy and severe malnutrition following duodenal switch.
Obes Surg 2008; 18: 1640-43
EUROPEAN ASSOCIATION FOR THE STUDY OF OBESITY
REGISTERED CHARITY NUMBER 1111288
32. Aasheim E, Bøhmer T. Low preoperative vitamin levels in morbidly
obese patients: a role of systemic inflammation? Surg Obes Relat
Dis 2008; 4: 779-80
33. Olsen T, Goll R, Cui G, Husebekk A, Vonen B, Birketvedt GS,
Florholmen J.Tissue levels of tumor necrosis factor-alpha
correlates with grade of inflammation in untreated ulcerative
colitis. Scan J Gastroenterol 2007; 42: 1312-20
34. Aasheim E, Mala T, Søvik TT, Kristinsson J, Bøhmer T. Surgical
treatment of morbid obesity. Tidsskr Nor Legeforen 2007; 127: 3842
35. Søvik TT, Aasheim E, Kristinsson J, Schou CF, Nesbakken A, Mala T.
Surgical treatment of morbid obesity at a regional center. Tidsskr
Nor Legeforen 2007; 127: 47-9
36. Birketvedt GS, Drivenes E, Agledahl I, Sundsfjord J, Olstad R,
Florholmen JR. Bulimia nervosa – a primary defect in the
hypothalamic-pituitary-adrenal axis? Appetite 2006; 46: 164-7
Applications will be evaluated twice per year. The first set of applications will be evaluated by the end of
the first quarter of 2012 (January - March) and the deadline for applications to be evaluated in this time period
is 31 December 2011.
This form should be completed in full and returned to the EASO Secretariat at enquiries@easo.org.
EUROPEAN ASSOCIATION FOR THE STUDY OF OBESITY
REGISTERED CHARITY NUMBER 1111288